128837-71-8

PKSI-527 (128837-71-8) is a selective plasma kallikrein inhibitor (Ki = 0.81 μM)1 that can be used for affinity purification of kallikrein2.? Synergizes with NO donors to produce antithrombic effects ex-vivo.3? Suppresses collagen-induced arthritis in mouse models.4

PKSI-527 is a new, highly selective plasma kallikrein inhibitor. PKSI-527 can suppress collagen-induced arthritis (CIA) by modifying the kallikrein-kinin system[1].

Wanaka et al. (1992), Synthesis of trans-4-aminomethylcyclohexanecarbonyl-L- and –D-phenylalanine-4-carboxymethylanilide and examination of their inhibitory activity against plasma kallikrein;? ?Chem. Pharm. Bull., 40 1814 Tada et al. (2001), Isolation of plasma kallikrein by high efficiency affinity chromatography and its characterization; Chem. Pharm. Bull., 24 520 Ikarugi et al. (2005), Synergistic antithrombotic effect of a combination of NO donor and plasma kallikrein inhibitor; Thromb. Res., 116 403 Fujimori et al. (1993), Effects of a highly selective plasma kallikrein inhibitor on collagen-induced arthritis in mice; Agents Actions, 39 42